| Autor: |
Booij, Jan, de Jong, Jan, de Bruin, Kora, Knol, Remco, de Win, Maartje M. L., van Eck-Smit, Berthe L. F. |
| Přispěvatelé: |
ANS - Amsterdam Neuroscience, Nuclear Medicine, Radiology and Nuclear Medicine, ACS - Amsterdam Cardiovascular Sciences |
| Jazyk: |
angličtina |
| Rok vydání: |
2007 |
| Zdroj: |
Journal of nuclear medicine, 48(3), 359-366. Society of Nuclear Medicine Inc. |
| ISSN: |
0161-5505 |
| Popis: |
Dopamine transporter (DAT) imaging with I-123-FP-CIT (I-123-N-omega-fluoropropyl-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane) SPECT is frequently used to detect loss of nigrostriatal cells in parkinsonism. Recent I-123-beta-CIT (I-123-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane) studies have shown a significant increase in striatal-to-nonspecific beta-CIT binding ratios after treatment with selective serotonin reuptake inhibitors (SSRIs). Due to similarities between I-123-beta-CIT and I-123-FP-CIT (both are derived from cocaine and show relatively high affinity for the DAT and the serotonin transporter [SERT]), we hypothesized that quantification of striatal I-123-FP-CIT binding may be influenced by SSRIs. Moreover, we hypothesized that I-123-FP-CIT in humans binds not only to DATs but also to central and peripheral SERTs. Methods: To study the influence of the SSRI paroxetine on I-123-FP-CIT binding to DATs in the striatum, we conducted a double-blind, placebo-controlled, crossover study with paroxetine in 8 healthy young male control subjects. In addition, we studied whet er paroxetine was able to block I-123-FP-CIT binding in SERT-rich brain areas and in lung tissue, as lung tissue contains a considerable amount of SERTs. Participants were pretreated for 2 d with paroxetine (20 mg/d) or placebo at 2 sessions (crossover design), and brain SPECT was performed 1 and 3 h after I-123-FP-CIT injection, whereas lung uptake was measured 2 h after injection. Results: Compared with placebo pretreatment, we found after paroxetine pretreatment a statistically significant increase (approximately 10%) in specific striatal-to-nonspecific I-123-FP-CIT binding ratios at 3 h after injection, a time point at which striatal I-123-FP-CIT binding ratios are stable. In addition, after paroxetine treatment, statistically significantly lower binding ratios were found in SERT-rich brain areas (e.g., at 1 h after injection, mid brain-to-cerebellar ratios were approximately 90% lower) as well as significantly lower uptake in lung tissue was found (approximately 40% lower after paroxetine). Conclusion: In this study we show that the quantification of striatal I-123-FPCIT binding to DAT is significantly increased by the SSRI paroxetine in humans. To our knowledge, this is the first study which shows that I-123-FP-CIT binds in vivo in humans not only to DATs but also to central SERTs and SERTs in lung tissue |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
